SCHEMBL1642864

SCHEMBL1642864

CC(C)NC(=O)c1c(O)c(C(=O)NCC(=O)O)c(=O)n(C2CCCCC2)c1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 14/20 0.66
EGLN3 Q9H6Z9 3/20 0.66
HIF1AN Q9NWT6 2/20 0.66
EGLN2 Q96KS0 2/20 0.66
OGFOD1 Q8N543 1/20 0.66
BBOX1 O75936 2/20 0.39
ASPH Q12797 2/20 0.39
KDM8 Q8N371 2/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 1/20 0.38
XBP1 P17861 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 1/20 0.37
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641734 0.92 EGLN1 (0.77) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1640786 0.90 EGLN1 (0.65) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1640372 0.90 EGLN1 (0.65) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1641386 0.89 EGLN1 (0.63) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1641888 0.89 EGLN1 (0.69) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1642340 0.87 EGLN1 (0.60) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1641194 0.85 EGLN1 (0.67) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1642217 0.85 EGLN1 (0.67) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1641845 0.85 EGLN1 (0.67) EGLN1EGLN3HIF1ANEGLN2OGFOD1
SCHEMBL1641949 0.85 EGLN1 (0.67) EGLN1EGLN3HIF1ANEGLN2OGFOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN1 6/4885EGLN3 3/4885HIF1AN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.